These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 15289858)

  • 1. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
    Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
    Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
    Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
    Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
    Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
    Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
    Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
    Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
    Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
    Murakami Y; Kazuno H; Emura T; Tsujimoto H; Suzuki N; Fukushima M
    Int J Oncol; 2000 Aug; 17(2):277-83. PubMed ID: 10891536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
    Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
    Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
    Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
    Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
    Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
    Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
    van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
    Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
    Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
    Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
    Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
    Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
    De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
    Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.